Ranibizumab (Lucentis; Genentech), a humanized monoclonal antibody fragment that binds to vascular endothelial growth factor, was approved by the US FDA in June 2006 for the treatment of patients with neovascular age-related macular degeneration.
- Raja Narayanan
- Baruch D. Kuppermann
- Peter Kirkpatrick